Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behçet's disease in Italian patients

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1547-1550

  Atzeni, F ^a   Boiardi, L ^b   Casali, B ^c   Farnetti, E ^c   Sarzi puttini, P ^a   Pipitone, N ^b   Olivieri, I ^d   Cantini, F ^e   Salvi, F ^f   La Corte, R ^g   Triolo, G ^h   Filippini, D ⁱ   Paolazzi, G ^j   Salvarani, Carlo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Unita Operativa di Reumatologia   (Italy)

^c Laboratorio di Biologia Molecolare   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e MISERICORDIA E DOLCE HOSPITAL   (Italy)

^f BELLARIA HOSPITAL   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j SANTA CHIARA HOSPITAL   (Italy)

more..

Author keywords

Beh et's disease; Disease manifestation; Myeloperoxidase; Myeloperoxidase gene polymorphism

Indexed keywords

HLA ANTIGEN CLASS 1; MYELOPEROXIDASE;

ADULT; ARTICLE; BEHCET DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE;

ADULT; BEHCET SYNDROME; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; PEROXIDASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 34848894587     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem224     Document Type: Article

References (44)

1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999;341:1284-91.
2. Direskeneli H. Behçet's disease: Infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001;60:996-1002.
3. Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin Rheumatol 2004;16:38-42.
4. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000;7:53-8.
5. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980;93:480-9.
6. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 2006;111:16-26.
7. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002;40:2-8.
8. Tuzun B, Tuzun Y, Yurdakul S, Hamuryudan V, Yazici H, Ozyazgan Y. Neutrophil chemotaxis in Behȩt's syndrome. Ann Rheum Dis 1999;58:658.
9. Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behçet's disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 1982;49:247-55.
10. Pronai L, Ichikawa Y, Nakazawa H, Arimori S. Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leukocytes in Behçet's disease-effects of colchicine. Clin Exp Rheumatol 1991;9:227-33.
11. Mege JL, Dilsen N, Sanguedolce V et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544-9.
12. Dogan P, Tanrikulu G, Soyuer U, Kose K. Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behçet's disease. Clin Biochem 1994;27:413-8.
13. Yazici C, Kose K, Calis M, Demir M, Kirnap M, Ates F. Increased advanced oxidation protein products in Behçet's disease: A new activity marker? Br J Dermatol 2004;151:105-11.
14. Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: Moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999;91:330-7.
15. Accardo-Palumbo A, Triolo G, Carbone MC et al. Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. Clin Exp Rheumatol 2000;18:495-8.
16. Rutgers A, Heeringa P, Giesen JE, Theunissen RT, Jacobs H, Tervaert JW. Neutrophil myeloperoxidase activity and the influence of two single-nucleotide promoter polymorphisms. Br J Haematol 2003;123:536-8.
17. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-7.
18. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
19. Reynolds WF, Rhees J, Maciejewski D et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999;155:31-41.
20. Rothkrantz-Kos S, Drent M, Rutgers A et al. Relationship between myeloperoxidase promotor polymorphism and disease severity in sarcoidosis. Eur J Intern Med 2003;14:296-301.
21. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
22. Reynolds WF, Stegeman CA, Tervaert JW. a463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002;103:154-60.
23. Pecoits-Filho R, Stenvinkel P, Marchlewska A et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int 2003;84:S172-6.
24. Makela R, Dastidar P, Jokela H et al. Relation of myeloperoxidase promoter polymorphism and long-term hormone replacement therapy to oxidized low-density lipoprotein autoantibodies in postmenopausal women. Scand J Clin Lab Invest 2006;66:371-83.
25. Pipitone N, Boiardi L, Olivieri I et al. Clinical manifestations of Behçet's disease in 137 Italian patients: Results of a multicenter study. Clin Exp Rheumatol 2004;22:S46-51.
26. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990;335:1078-80.
27. Terasaki PI, McClelland JD. Microdroplet assay for human serum cytotoxins. Nature 1964;204:998-1000.
28. Sambrook J, Fritsch EF, Maniatis T. In: Nolan C, ed. Molecular Cloning. A laboratory manual. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1989;9-17.
29. Salvarani C, Boiardi L, Mantovani V et al. Association of MICA alleles and HLA-B51 in Italian patients with Behçet's disease. J Rheumatol 2001;28:1867-70.
30. Boiardi L, Salvarani C, Casali B et al. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's Disease. J Rheumatol 2001;28:1283-7.
31. Salvarani C, Boiardi L, Casali B et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. J Rheumatol 2002;29:535-40.
32. Salvarani C, Boiardi L, Casali B et al. Vascular endothelial growth factor gene polymorphisms in Behçet's disease. J Rheumatol 2004;31:1785-9.
33. Kobayashi M, Ito M, Nakagawa A et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 2000;36:362-71.
34. Taysi S, Demircan B, Akdeniz N, Atasoy M, Sari RA. Oxidant/antioxidant status in men with Behçet's disease. Clin Rheumatol 2007;26:418-22.
35. Sepici-Dincel A, Ozkan Y, Yardim-Akaydin S, Kaymak-Karatas G, Onder M, Simsek B. The association between total antioxidant status and oxidative stress in Behçet's disease. Rheumatol Int 2006;26:1005-9.
36. Buldanlioglu S, Turkmen S, Ayabakan HB et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Br J Dermatol 2005;153:526-30.
37. Gunduz K, Ozturk G, Sozmen EY. Erythrocyte superoxide dismutase, catalase activities and plasma nitrite and nitrate levels in patients with Behcet disease and recurrent aphthous stomatitis. Clin Exp Dermatol 2004;29:176-9.
38. Sandikci R, Turkmen S, Guvenen G et al. Lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease. Acta Derm Venereol 2003;83:342-6.
39. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 2001;37:517-20.
40. Zakrzewska-Pniewska B, Styczynska M, Podlecka A et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004;10:266-71.
41. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9.
42. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, Jessurun GA, Tio RA. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004;116:429-30.
43. Salvarani C, Casali B, Farnetti E et al. -463 G/A Myeloperoxidase promoter polymorphism in giant cell arteritis. Ann Rheum Dis (in press).
44. Fiebeler A, Borgmann S, Woywodt A, Haller H, Haubitz M. No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis. Nephrol Dial Transplant 2004;19:969-71.